Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Karyopharm Therapeutics (25K0) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Ruxolitinib, Pacritinib, Momelotinib, Selinexor 60 Mg, Selinexor 40 MgMyelofibrosis, Moderate ThrombocytopeniaPhase IIRecruitingA Study of Selinexor Monotherapy in Subjects with JAK Inhibitor-naïve Myelofibrosis and Moderate ThrombocytopeniaJul 24, 2023―
SelinexorEndometrial CancerPhase IIIRecruitingSelinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial CarcinomaNov 03, 2022―
Pembrolizumab, Selinexor, Trifluridine, TipiracilMetastatic Colorectal CancerPhase IITerminatedA Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS MutationsApr 17, 2021―
Lenalidomide, Daratumumab, Selinexor, Dexamethasone OralMultiple Myeloma, Plasma Cell Myeloma, Myeloma Multiple, Kahler Disease, Myeloma, Plasma Cell, Myeloma-Multiple, MyelomatosisPhase IIActive Not RecruitingStudy of Selinexor Plus DRd for Newly Diagnosed Multiple MyelomaMar 01, 2021―
Pembrolizumab, SelinexorLocally Advanced Unresectable Or Metastatic MelanomaPhase IITerminatedSafety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced MelanomaFeb 22, 2021―
Lenalidomide, Oxaliplatin, Gemcitabine, Venetoclax, Rituximab, Selinexor, Bendamustine, Ibrutinib, Polatuzumab Vedotin, TafasitamabRelapsed Or Refractory Diffuse Large B-Cell Lymphomaphase1AndPhase2WithdrawnStudy of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)Oct 26, 2020
Ruxolitinib, SelinexorMyelofibrosisPhase IIIActive Not RecruitingStudy of Selinexor in Combination With Ruxolitinib in MyelofibrosisSep 14, 2020―
Selinexor, Physician's Choice TreatmentMyelofibrosisPhase IIActive Not RecruitingA Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated MyelofibrosisSep 09, 2020―
Lenalidomide, Selinexor, MethylprednisoloneRefractory Multiple MyelomaPhase IRecruitingSelinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.Aug 12, 2020―
Selinexor (Combination Therapy), Rituximab (Combination Therapy), Gemcitabine (Combination Therapy), Dexamethasone (Combination Therapy), Cisplatin (Combination Therapy), Selinexor (Continuous Therapy)Relapsed/Refractory Diffuse Large B-Cell Lymphomaphase2AndPhase3RecruitingA Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaJun 10, 2020―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Karyopharm Therapeutics INC (DE:25K0) have in its pipeline
Karyopharm Therapeutics DE:25K0 is currently developing the following drugs: Ruxolitinib, Pacritinib, Momelotinib, Selinexor 60 Mg, Selinexor 40 Mg, Selinexor, Pembrolizumab, Selinexor, Trifluridine, Tipiracil, Lenalidomide, Daratumumab, Selinexor, Dexamethasone Oral, Pembrolizumab, Selinexor, Lenalidomide, Oxaliplatin, Gemcitabine, Venetoclax, Rituximab, Selinexor, Bendamustine, Ibrutinib, Polatuzumab Vedotin, Tafasitamab, Ruxolitinib, Selinexor, Selinexor, Physician's Choice Treatment, Lenalidomide, Selinexor, Methylprednisolone, Selinexor (Combination Therapy), Rituximab (Combination Therapy), Gemcitabine (Combination Therapy), Dexamethasone (Combination Therapy), Cisplatin (Combination Therapy), Selinexor (Continuous Therapy), Dexamethasone, Selinexor, Bortezomib, Bevacizumab, Selinexor, Temozolomide (Tmz), Lomustine (Ccnu), Standard Fractionated Radiation Therapy (Rt), Ttfield, Carmustine, Pembrolizumab, Docetaxel, Folfiri, Selinexor 60 Mg, Selinexor 40 Mg, Selinexor 100 Mg, Selinexor 80 Mg, Nivolumab, Kpt-9274, Niacin Er, Dexamethasone, Kpt-8602, Astx727, Dexamethasone, Carfilzomib, Selinexor, Verdinexor, Lenalidomide, Dexamethasone, Selinexor, Selinexor, Vehicle Gel, Standard-Of-Care, Lenalidomide, Dexamethasone, Daratumumab, Carfilzomib, Pomalidomide, Elotuzumab, Selinexor, Bortezomib, Belantamab Mafodotin, Clarithromycin, Ixazomib, Mezigdomide, Dexamethasone, Selinexor, Selinexor (Kpt-330), Selinexor, Hydroxyurea, Ara-C, Kcp-330, Kpt-330, Selinexor, Acetaminophen. These drug candidates are in various stages of clinical development as the company works toward FDA approval.